ZA200705540B - Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation - Google Patents

Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation

Info

Publication number
ZA200705540B
ZA200705540B ZA200705540A ZA200705540A ZA200705540B ZA 200705540 B ZA200705540 B ZA 200705540B ZA 200705540 A ZA200705540 A ZA 200705540A ZA 200705540 A ZA200705540 A ZA 200705540A ZA 200705540 B ZA200705540 B ZA 200705540B
Authority
ZA
South Africa
Prior art keywords
prevention
compositions
treatment
airway inflammation
pde4 modulators
Prior art date
Application number
ZA200705540A
Other languages
English (en)
Inventor
Jerome B Zeldis
Patricia E W Rohane
Peter H Schafer
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of ZA200705540B publication Critical patent/ZA200705540B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
ZA200705540A 2004-12-13 2005-12-12 Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation ZA200705540B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63498204P 2004-12-13 2004-12-13

Publications (1)

Publication Number Publication Date
ZA200705540B true ZA200705540B (en) 2009-01-28

Family

ID=36121316

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705540A ZA200705540B (en) 2004-12-13 2005-12-12 Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation

Country Status (13)

Country Link
US (1) US20060148882A1 (enExample)
EP (1) EP1838294A1 (enExample)
JP (1) JP2008523102A (enExample)
KR (1) KR20070092276A (enExample)
CN (1) CN101111235A (enExample)
AR (1) AR052047A1 (enExample)
AU (1) AU2005316593A1 (enExample)
BR (1) BRPI0519030A2 (enExample)
CA (1) CA2590903A1 (enExample)
IL (1) IL183858A0 (enExample)
MX (1) MX2007006992A (enExample)
WO (1) WO2006065814A1 (enExample)
ZA (1) ZA200705540B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
CA2563377A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
MY160002A (en) * 2009-02-10 2017-02-15 Celgene Corp Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
KR101514866B1 (ko) 2009-05-14 2015-04-24 티안진 헤메이 바이오-텍 컴퍼니 리미티드 티오펜 유도체
WO2011127019A2 (en) * 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
MX354210B (es) 2010-12-16 2018-02-16 Celgene Corp Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
ES2632979T3 (es) * 2011-01-10 2017-09-18 Celgene Corporation Formas de dosificación oral de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida de ácido ciclopropanocarboxílico
ES2673114T3 (es) * 2011-01-10 2018-06-19 Celgene Corporation Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas
ES2711100T3 (es) * 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
ES2661583T3 (es) 2011-04-28 2018-04-02 Celgene Corporation Métodos y composiciones usando inhibidores de PDE4 para el tratamiento y gestión de enfermedades autoinmunes e inflamatorias
US9872854B2 (en) 2013-03-14 2018-01-23 Celgene Corporation Methods for the treatment of psoriatic arthritis using apremilast
EP3096749B1 (en) * 2014-01-24 2019-05-15 Celgene Corporation Methods for the treatment of obesity using apremilast
WO2016025686A1 (en) 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
US10011611B2 (en) 2015-08-14 2018-07-03 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
WO2018036469A1 (zh) * 2016-08-22 2018-03-01 南京明德新药研发股份有限公司 Pde4抑制剂
US11337964B2 (en) * 2017-02-28 2022-05-24 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, pharmaceutical composition and use thereof
CN110573148A (zh) * 2017-03-16 2019-12-13 武田有限公司 特发性肺纤维化的治疗
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2004043378A2 (en) * 2002-11-06 2004-05-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
KR20050075435A (ko) * 2002-11-18 2005-07-20 셀진 코포레이션 (＋)-３-(３,４-디메톡시-페닐)-３-(１-옥소-１,３-디히드로-이소인돌-２-일)-프로피온아미드의 사용 방법 및 그를포함하는 조성물
KR20050090435A (ko) * 2002-12-30 2005-09-13 셀진 코포레이션 플루오로알콕시-치환된 1,3-디히드로-이소인돌릴 화합물 및그의 제약학적 용도
CA2563377A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
CN1984651A (zh) * 2004-05-05 2007-06-20 细胞基因公司 使用选择性细胞因子抑制药治疗和控制癌症和其它疾病的方法和组合物
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same

Also Published As

Publication number Publication date
BRPI0519030A2 (pt) 2008-12-23
JP2008523102A (ja) 2008-07-03
AR052047A1 (es) 2007-02-28
US20060148882A1 (en) 2006-07-06
IL183858A0 (en) 2007-10-31
CA2590903A1 (en) 2006-06-22
CN101111235A (zh) 2008-01-23
KR20070092276A (ko) 2007-09-12
WO2006065814A1 (en) 2006-06-22
EP1838294A1 (en) 2007-10-03
AU2005316593A1 (en) 2006-06-22
MX2007006992A (es) 2007-08-03

Similar Documents

Publication Publication Date Title
IL183858A0 (en) Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
ZA200704677B (en) Compositions and methods for the treatment of autism
IL182574A0 (en) Gpr41 and modulators thereof for the treatment of insulin-related disorders
PT1594867E (pt) Fenilacetamidas e sua utilização como moduladores de glucocinase
IL178860A (en) Certain chemical entities, preparations and processes
IL181369A0 (en) Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder
IL187565A0 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
AU2003291480A8 (en) Composition for the prevention and treatment of inflammation of the ear
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
EP1809272A4 (en) METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS
IL178788A0 (en) Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
EP2056857A4 (en) PHARMACEUTICAL COMPOSITIONS WITH CCL2 AND THEIR USE IN THE TREATMENT OF INFLAMMATION
IL187405A0 (en) Methods and compositions for the treatment of pain
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
EP1814567A4 (en) USE OF MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING AND PREVENTING INFECTIONS
IL198721A0 (en) Acat inhibitors and their use in the prevention or treatment of fibrosis
ZA200800981B (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
IL181777A0 (en) Gpr43 and modulators thereof for the treatment of metabolic-related disorders
SI1812797T1 (sl) Pripravki in metode zdravljenja ter preprečevanja hiperprolifetarivnih bolezni
GB0425633D0 (en) Topical formulations for use in the treatment or prevention of dermatological conditions
EP1819724A4 (en) BETA 2-GLYCOPROTEIN I COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
IL177751A0 (en) Pharmaceutical composition of (+)-erythro-mefloquine and its use